Envestnet Asset Management
CYTK icon

Envestnet Asset Management’s Cytokinetics CYTK Stock Holding History

Envestnet Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.54M Buy
88,521
+53,984
+156% +$3.88M ﹤0.01% 2144
2026
Q1 		$2.28M Sell
34,537
-28,196
-45% -$1.79M ﹤0.01% 2922
2025
Q4 		$3.99M Buy
62,733
+3,665
+6% +$228K ﹤0.01% 2336
2025
Q3 		$3.25M Buy
59,068
+29,601
+100% +$1.22M ﹤0.01% 2549
2025
Q2 		$974K Buy
29,467
+5,146
+21% +$179K ﹤0.01% 3295
2025
Q1 		$977K Sell
24,321
-2,134
-8% -$98.1K ﹤0.01% 3224
2024
Q4 		$1.24M Sell
26,455
-6,612
-20% -$343K ﹤0.01% 3013
2024
Q3 		$1.75M Buy
33,067
+2,441
+8% +$136K ﹤0.01% 2757
2024
Q2 		$1.66M Buy
30,626
+6,127
+25% +$370K ﹤0.01% 2707
2024
Q1 		$1.72M Buy
24,499
+3,742
+18% +$289K ﹤0.01% 2675
2023
Q4 		$1.73M Sell
20,757
-7,200
-26% -$261K ﹤0.01% 2565
2023
Q3 		$824K Buy
27,957
+7,043
+34% +$235K ﹤0.01% 2943
2023
Q2 		$682K Sell
20,914
-430
-2% -$15.9K ﹤0.01% 3037
2023
Q1 		$751K Buy
21,344
+72
+0.3% +$2.94K ﹤0.01% 2871
2022
Q4 		$975K Sell
21,272
-2,399
-10% -$103K ﹤0.01% 2666
2022
Q3 		$1.15M Sell
23,671
-365
-2% -$17.6K ﹤0.01% 2462
2022
Q2 		$944K Buy
24,036
+4,202
+21% +$169K ﹤0.01% 2642
2022
Q1 		$730K Buy
19,834
+1,419
+8% +$50.4K ﹤0.01% 2886
2021
Q4 		$839K Buy
18,415
+2,650
+17% +$102K ﹤0.01% 2738
2021
Q3 		$563K Sell
15,765
-4,712
-23% -$139K ﹤0.01% 2902
2021
Q2 		$405K Buy
20,477
+1,680
+9% +$39.4K ﹤0.01% 3106
2021
Q1 		$437K Buy
18,797
+6,900
+58% +$147K ﹤0.01% 2921
2020
Q4 		$247K Sell
11,897
-1,742
-13% -$31.8K ﹤0.01% 3023
2020
Q3 		$295K Buy
13,639
+894
+7% +$20.9K ﹤0.01% 2739
2020
Q2 		$300K Sell
12,745
-7,359
-37% -$138K ﹤0.01% 2683
2020
Q1 		$237K Buy
+20,104
New +$256K ﹤0.01% 2662

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Envestnet Asset Management's CYTK Position: Q2 2026 in Review

Envestnet Asset Management increased its Cytokinetics (CYTK) stake by 156% in Q2 2026, buying an estimated $3.88M and bringing the position to 88,521 shares worth $7.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2144.

Envestnet Asset Management first reported a position in CYTK in Q1 2020 and has held it in 26 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Envestnet Asset Management held 88,521 shares of Cytokinetics worth $7.54M as of Q2 2026.
  • Envestnet Asset Management bought 53,984 Cytokinetics shares in Q2 2026, an estimated $3.88M.
  • Cytokinetics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2144 holding.
  • Envestnet Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 26 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.